D8890
Dipyrone
analytical standard
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Linear Formula:
C13H16N3O4SNa
CAS Number:
Molecular Weight:
333.34
UNSPSC Code:
41116107
PubChem Substance ID:
EC Number:
200-694-7
MDL number:
grade
analytical standard
technique(s)
HPLC: suitable, gas chromatography (GC): suitable
application(s)
forensics and toxicology
veterinary
format
neat
storage temp.
2-8°C
SMILES string
[Na].CN(CS(O)(=O)=O)C1=C(C)N(C)N(C1=O)c2ccccc2
Application
Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.
Biochem/physiol Actions
A non-steroidal anti-inflammatory drug that, when coadministered with morphine, potentiates its antinociceptive action and delays the development of tolerance. Dipyrone is a relatively selective inhibitor of cyclooxygenase-3 (COX-3), with lower activity against COX-1 and no activity against COX-2. Blocks PGE2-induced hyperalgesia in several models.
signalword
Danger
hcodes
Hazard Classifications
Resp. Sens. 1 - Skin Sens. 1
Storage Class
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Joel E Schlosburg et al.
Behavioural pharmacology, 23(7), 722-726 (2012-09-08)
Dipyrone is a common nonopioid analgesic and antipyretic, which, in many countries, is available over the counter and is more widely used than paracetamol or aspirin. However, the exact mechanisms by which dipyrone acts remain inconclusive. Two novel arachidonoyl-conjugated metabolites
Márcia Germana Alves de Araújo Lobo et al.
BMC pharmacology & toxicology, 14, 5-5 (2013-01-10)
Adverse drug reactions (ADRs) are recognised as a common cause of hospital admissions, and they constitute a significant economic burden for hospitals. Hospital-based ADR monitoring and reporting programmes aim to identify and quantify the risks associated with the use of
M Levy et al.
Clinical pharmacokinetics, 28(3), 216-234 (1995-03-01)
The pharmacokinetics of dipyrone are characterised by rapid hydrolysis to the active moiety 4-methyl-amino-antipyrine (MAA), which has 85% bioavailability after oral administration in tablet form, and takes a short time to achieve maximal systemic concentrations (tmax of 1.2 to 2.0